Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT
The effect of subchronic treatment with l‐dopa/carbidopa or l‐selegiline on striatal dopamine transporters (DAT) was examined in patients with idiopathic Parkinson's disease with SPECT (single photon emission computed tomography) using [123I]β‐CIT (2β‐carbomethoxy‐3β‐[4‐iodophenyl]tropane) as t...
Saved in:
Published in | Movement disorders Vol. 14; no. 3; pp. 436 - 442 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
John Wiley & Sons, Inc
01.05.1999
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The effect of subchronic treatment with l‐dopa/carbidopa or l‐selegiline on striatal dopamine transporters (DAT) was examined in patients with idiopathic Parkinson's disease with SPECT (single photon emission computed tomography) using [123I]β‐CIT (2β‐carbomethoxy‐3β‐[4‐iodophenyl]tropane) as the radiotracer. Patients who were not currently being treated with these medications were given either 750 mg l‐dopa/carbidopa per day (n = 8) or 10 mg l‐selegiline per day (n = 8). [123I]β‐CIT imaging was performed three times in each patient: at baseline before treatment, while on medication and after 4–6 weeks of drug treatment, and following withdrawal from medication (approximately 1 week for l‐dopa/carbidopa and 9 weeks for l‐selegiline). Comparison of scans 2 and 3 provided a measure of drug occupancy of the [123I]β‐CIT binding site; comparison of scans 1 and 2 provided a measure of both up‐ or downregulation of DAT levels and drug occupancy following subchronic drug treatment. DAT levels were assessed from an image acquired approximately 22 hours after radiotracer injection as a ratio of regional brain activities: (striatum − occipital)/occipital. Striatal DAT levels were not significantly different when any two of the three scans were compared for both drug treatments. These results suggest that typical clinical doses of l‐dopa/carbidopa and l‐selegiline do not induce significant occupancy of the [123I]β‐CIT binding site and that 4–6 weeks of treatment causes no significant modulation of DAT levels. These results support the validity of measuring DAT levels with [123I]β‐CIT without the need to withdraw patients from medication treatment. |
---|---|
AbstractList | The effect of subchronic treatment with l‐dopa/carbidopa or l‐selegiline on striatal dopamine transporters (DAT) was examined in patients with idiopathic Parkinson's disease with SPECT (single photon emission computed tomography) using [123I]β‐CIT (2β‐carbomethoxy‐3β‐[4‐iodophenyl]tropane) as the radiotracer. Patients who were not currently being treated with these medications were given either 750 mg l‐dopa/carbidopa per day (n = 8) or 10 mg l‐selegiline per day (n = 8). [123I]β‐CIT imaging was performed three times in each patient: at baseline before treatment, while on medication and after 4–6 weeks of drug treatment, and following withdrawal from medication (approximately 1 week for l‐dopa/carbidopa and 9 weeks for l‐selegiline). Comparison of scans 2 and 3 provided a measure of drug occupancy of the [123I]β‐CIT binding site; comparison of scans 1 and 2 provided a measure of both up‐ or downregulation of DAT levels and drug occupancy following subchronic drug treatment. DAT levels were assessed from an image acquired approximately 22 hours after radiotracer injection as a ratio of regional brain activities: (striatum − occipital)/occipital. Striatal DAT levels were not significantly different when any two of the three scans were compared for both drug treatments. These results suggest that typical clinical doses of l‐dopa/carbidopa and l‐selegiline do not induce significant occupancy of the [123I]β‐CIT binding site and that 4–6 weeks of treatment causes no significant modulation of DAT levels. These results support the validity of measuring DAT levels with [123I]β‐CIT without the need to withdraw patients from medication treatment. The effect of subchronic treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporters (DAT) was examined in patients with idiopathic Parkinson's disease with SPECT (single photon emission computed tomography) using [123I]beta-CIT (2beta-carbomethoxy-3beta-[4-iodophenyl]tropane) as the radiotracer. Patients who were not currently being treated with these medications were given either 750 mg L-dopa/carbidopa per day (n = 8) or 10 mg L-selegiline per day (n = 8). [123I]beta-CIT imaging was performed three times in each patient: at baseline before treatment, while on medication and after 4-6 weeks of drug treatment, and following withdrawal from medication (approximately 1 week for L-dopa/carbidopa and 9 weeks for L-selegiline). Comparison of scans 2 and 3 provided a measure of drug occupancy of the [123I]beta-CIT binding site; comparison of scans 1 and 2 provided a measure of both up- or downregulation of DAT levels and drug occupancy following subchronic drug treatment. DAT levels were assessed from an image acquired approximately 22 hours after radiotracer injection as a ratio of regional brain activities: (striatum - occipital)/occipital. Striatal DAT levels were not significantly different when any two of the three scans were compared for both drug treatments. These results suggest that typical clinical doses of L-dopa/carbidopa and L-selegiline do not induce significant occupancy of the [123I]beta-CIT binding site and that 4-6 weeks of treatment causes no significant modulation of DAT levels. These results support the validity of measuring DAT levels with [123I]beta-CIT without the need to withdraw patients from medication treatment. |
Author | Sheff, Kim Feigin, Andrew Zoghbi, Sami Seibyl, John P. Marek, Kenneth L. Innis, Robert B. Castronuovo, Joseph |
Author_xml | – sequence: 1 givenname: Robert B. surname: Innis fullname: Innis, Robert B. organization: Departments of Psychiatry, Neurology, Pharmacology, and Diagnostic Radiology, Yale University School of Medicine – sequence: 2 givenname: Kenneth L. surname: Marek fullname: Marek, Kenneth L. organization: Departments of Psychiatry, Neurology, Pharmacology, and Diagnostic Radiology, Yale University School of Medicine – sequence: 3 givenname: Kim surname: Sheff fullname: Sheff, Kim organization: Departments of Psychiatry, Neurology, Pharmacology, and Diagnostic Radiology, Yale University School of Medicine – sequence: 4 givenname: Sami surname: Zoghbi fullname: Zoghbi, Sami organization: Departments of Psychiatry, Neurology, Pharmacology, and Diagnostic Radiology, Yale University School of Medicine – sequence: 5 givenname: Joseph surname: Castronuovo fullname: Castronuovo, Joseph organization: Departments of Neurology and Nuclear Medicine, North Shore University Hospital, Manhasset and Glen Cove, New York, U.S.A – sequence: 6 givenname: Andrew surname: Feigin fullname: Feigin, Andrew organization: Departments of Neurology and Nuclear Medicine, North Shore University Hospital, Manhasset and Glen Cove, New York, U.S.A – sequence: 7 givenname: John P. surname: Seibyl fullname: Seibyl, John P. organization: Departments of Psychiatry, Neurology, Pharmacology, and Diagnostic Radiology, Yale University School of Medicine |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1775199$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10348466$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkd1u0zAYhi00xLrBLaAcIAQH6ew4jp2CkEZWSkdZkVbEAUKWnXwphvwU29UYl8WFcE04alc4svXq8St_33OCjrq-A4RygscE4-SMMEpikTD-jOR5jtlzkk7oy5Rmk8n5_CJ-f3EdMPGKjvG4WL5I4st7aHR4c4RGWAgWUyLYMTpx7hvGhDCSPUDHBNNUpFk2Qr-mdQ2lj_o68haUb6Hz0Y3xX6NFXPUbdVYqq81wi3obMgcNrE1jOoj6LnLeGuVVEw1AO4Teqs5teuvBRtcfpsUqMq1am269K_1MEjr_8ud3XMxXD9H9WjUOHu3PU_TxzXRVvI0Xy9m8OF_EhrJExMB0qgjhTFSQcqIVJQlPK810WSUcWKIFT1UIgJXA8hJrjUUlNFBBNJQVPUVPd70b2__YgvOyNa6EplEd9Fsns5yLLEtZAB_vwa1uoZIbG_5ub-XdtgLwZA8oV6qmDrOWxv3jOGdBFD0McmMauP2vRg5W5WBIDobkzqokqaQyWJVBqtxLDQmWxVIm8vIuCr3xrtc4Dz8Pvcp-lxmnnMlPVzOZv55dsVX-TlL6F1PTqt0 |
ContentType | Journal Article |
Copyright | Copyright © 1999 Movement Disorder Society 1999 INIST-CNRS |
Copyright_xml | – notice: Copyright © 1999 Movement Disorder Society – notice: 1999 INIST-CNRS |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM 7X8 8BM |
DOI | 10.1002/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic ComDisDome |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ComDisDome MEDLINE - Academic |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1531-8257 |
EndPage | 442 |
ExternalDocumentID | 10348466 1775199 MDS1008 ark_67375_WNG_9BGN5T9K_3 |
Genre | article Research Support, U.S. Gov't, Non-P.H.S Controlled Clinical Trial Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Guilford Pharmaceuticals Inc. (Baltimore, MD) – fundername: the National Parkinson's Foundation – fundername: the Department of Veterans Affairs (Merit Review Award) |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 123 1CY 1L6 1OB 1OC 1ZS 31~ 33P 3PY 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAVGM AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABHUG ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXME ACXQS ADAWD ADBBV ADBTR ADDAD ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFVGU AFZJQ AGJLS AHBTC AHMBA AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWD RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TWZ UB1 V2E V9Y W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR XG1 XV2 YCJ ZGI ZZTAW ~IA ~WT AITYG HGLYW OIG AAPBV IQODW CGR CUY CVF ECM EIF NPM 7X8 8BM |
ID | FETCH-LOGICAL-i3528-e5b4a11758de471ba31274db5bcd27e52b874a4dbe5ce59c0bb08d8be381becd3 |
IEDL.DBID | DR2 |
ISSN | 0885-3185 |
IngestDate | Fri Aug 16 23:24:28 EDT 2024 Sat Sep 28 07:34:52 EDT 2024 Sun Oct 29 17:08:09 EDT 2023 Sat Aug 24 00:56:50 EDT 2024 Wed Jan 17 05:01:59 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Radionuclide study Subchronic Carbidopa Biological transport Parkinson disease Lyases Carboxy-lyases Adult Degenerative disease Levodopa Mechanism of action Human Selegiline Nervous system diseases Drug combination Decarboxylase Dopamine Enzyme Idiopathic Enzyme inhibitor Corpus striatum Antiparkinson agent Photon Cerebral disorder Carbon-carbon lyases Chemotherapy MAO B inhibitor Treatment Central nervous system disease Extrapyramidal syndrome Emission tomography |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-i3528-e5b4a11758de471ba31274db5bcd27e52b874a4dbe5ce59c0bb08d8be381becd3 |
Notes | the Department of Veterans Affairs (Merit Review Award) the National Parkinson's Foundation ark:/67375/WNG-9BGN5T9K-3 ArticleID:MDS1008 istex:3A960777901D76285C804BFDFDC9C22BA1D38C9C Guilford Pharmaceuticals Inc. (Baltimore, MD) ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 10348466 |
PQID | 69786645 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_69786645 pubmed_primary_10348466 pascalfrancis_primary_1775199 wiley_primary_10_1002_1531_8257_199905_14_3_436_AID_MDS1008_3_0_CO_2_J_MDS1008 istex_primary_ark_67375_WNG_9BGN5T9K_3 |
PublicationCentury | 1900 |
PublicationDate | May 1999 |
PublicationDateYYYYMMDD | 1999-05-01 |
PublicationDate_xml | – month: 05 year: 1999 text: May 1999 |
PublicationDecade | 1990 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: Hoboken, NJ – name: United States |
PublicationTitle | Movement disorders |
PublicationTitleAlternate | Mov. Disord |
PublicationYear | 1999 |
Publisher | John Wiley & Sons, Inc Wiley |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley |
References | Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991;9:43-49. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the stratum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological, and neurochemical correlations. J Neurol Sci 1973;20:415-455. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporter binding in human striatum with [123I]β-CIT SPECT. J Nucl Med 1995;36:1175-1181. Seibyl JP, Laruelle M, van Dyck CH, et al. Reproducibility of [123I]β-CIT SPECT brain measurement of dopamine transporters in healthy human subjects. J Nucl Med 1996;37:222-227. Calne DB, Langston JW, Martin WRW, et al. PET after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985;317:246-248. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577-583. Baldwin RM, Zea-Ponce Y, Zoghbi SS, et al. Evaluation of the monoamine uptake site ligand [123I]methyl 3β-(4-iodophenyl)tropane-2β-carboxylate ([123I]β-CIT) in nonhuman primates: pharmacokinetics, biodistribution, and SPECT brain imaging coregistered with MRI. Nucl Med Biol 1993;20:597-606. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993;115:1-17. Diggle P, Kung-yee L, Zeger S. Analysis of Longitudinal Data. New York, NY: Oxford Science Publications, 1994. Bredberg E, Tedroff J, Aquilonius SM, Paalzow L. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. Eur J Clin Pharmacol 1990;39:358-389. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomographic imaging of the dopamine transporter with C-11-Win 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978;25:638-643. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-11969. Fang J, Yu PH. Effect of l-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 1994;33:763-768. Seibyl JP, Zea-Ponce Y, Brenner L, et al. Continuous intravenous infusion of [123I]IBZM for SPECT imaging of human brain dopamine receptors: occupancy by the novel antipsychotic RWJ-37796. J Nucl Med 1996;37:11-15. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by PET in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298. Asenbaum S, Brücke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease. J Nucl Med 1997;38:1-6. Seibyl J, Marek K, Sheff K, et al. Test/retest reproducibility of [123I]β-CIT SPECT brain measurement of dopamine transporters in Parkinson's disease. J Nucl Med 1997;38:1453-1458. Rudnick G, Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1993;1144:249-263. Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994. Schoemaker H, Pimoule C, Arbilla S, Javoy-Agid F, Langer SZ. Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease. Naunyn Schmiedeberg's Arch Pharmacol 1985;329:227-235. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991;56:192-198. Reynolds GP, Riederer P, Sandler M, Jellinger K, Seeman P. Amphetamine and 2-phenylethylamine in post-mortem parkinsonian brain after (−)-deprenyl administration. J Neural Transm 1978;43:271-277. Laruelle M, Baldwin RM, Malison RT, et al. SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I]β-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's diseases. Neurology 1996;46:231-237. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease. Ann Neurol 1995;38:589-598. 1987; 2 1985; 329 1991; 56 1995; 38 1990; 39 1995; 36 1993; 20 1994 1993; 90 1991; 9 1995; 294 1996; 37 1993; 13 1993; 34 1973; 20 1990; 47 1978; 43 1967; 17 1994; 33 1994; 14 1993; 1144 1997; 38 1978; 25 1985; 317 1996; 46 1988; 318 1993; 115 |
References_xml | – volume: 318 start-page: 876 year: 1988 end-page: 880 article-title: Uneven pattern of dopamine loss in the stratum of patients with idiopathic Parkinson's disease publication-title: N Engl J Med – volume: 20 start-page: 597 year: 1993 end-page: 606 article-title: Evaluation of the monoamine uptake site ligand [ I]methyl 3β‐(4‐iodophenyl)tropane‐2β‐carboxylate ([ I]β‐CIT) in nonhuman primates: pharmacokinetics, biodistribution, and SPECT brain imaging coregistered with MRI publication-title: Nucl Med Biol – volume: 317 start-page: 246 year: 1985 end-page: 248 article-title: PET after MPTP: observations relating to the cause of Parkinson's disease publication-title: Nature – volume: 115 start-page: 1 year: 1993 end-page: 17 article-title: Functional imaging in relation to parkinsonian syndromes publication-title: J Neurol Sci – volume: 39 start-page: 358 year: 1990 end-page: 389 article-title: Pharmacokinetics and effects of levodopa in advanced Parkinson's disease publication-title: Eur J Clin Pharmacol – volume: 38 start-page: 1 year: 1997 end-page: 6 article-title: Imaging of dopamine transporters with iodine‐123‐β‐CIT and SPECT in Parkinson's disease publication-title: J Nucl Med – volume: 13 start-page: 295 year: 1993 end-page: 309 article-title: SPECT imaging of dopamine and serotonin transporters with [ I]β‐CIT: pharmacological characterization of brain uptake in nonhuman primates publication-title: Synapse – volume: 37 start-page: 11 year: 1996 end-page: 15 article-title: Continuous intravenous infusion of [ I]IBZM for SPECT imaging of human brain dopamine receptors: occupancy by the novel antipsychotic RWJ‐37796 publication-title: J Nucl Med – volume: 43 start-page: 271 year: 1978 end-page: 277 article-title: Amphetamine and 2‐phenylethylamine in post‐mortem parkinsonian brain after (−)‐deprenyl administration publication-title: J Neural Transm – volume: 9 start-page: 43 year: 1991 end-page: 49 article-title: Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum publication-title: Synapse – volume: 25 start-page: 638 year: 1978 end-page: 643 article-title: A method for attenuation correction in radionuclide computed tomography publication-title: IEEE Trans Nucl Sci – volume: 20 start-page: 415 year: 1973 end-page: 455 article-title: Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological, and neurochemical correlations publication-title: J Neurol Sci – volume: 17 start-page: 427 year: 1967 end-page: 442 article-title: Parkinsonism: onset, progression, and mortality publication-title: Neurology – volume: 38 start-page: 589 year: 1995 end-page: 598 article-title: Decreased single‐photon emission computed tomographic [ I]β‐CIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease publication-title: Ann Neurol – volume: 38 start-page: 1453 year: 1997 end-page: 1458 article-title: Test/retest reproducibility of [ I]β‐CIT SPECT brain measurement of dopamine transporters in Parkinson's disease publication-title: J Nucl Med – year: 1994 – volume: 1144 start-page: 249 year: 1993 end-page: 263 article-title: From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters publication-title: Biochim Biophys Acta – volume: 46 start-page: 231 year: 1996 end-page: 237 article-title: [ I]β‐CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi‐Parkinson's diseases publication-title: Neurology – volume: 47 start-page: 1290 year: 1990 end-page: 1298 article-title: The nigrostriatal dopaminergic system assessed by PET in healthy volunteer subjects and patients with Parkinson's disease publication-title: Arch Neurol – volume: 329 start-page: 227 year: 1985 end-page: 235 article-title: Sodium dependent [ H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease publication-title: Naunyn Schmiedeberg's Arch Pharmacol – volume: 36 start-page: 1175 year: 1995 end-page: 1181 article-title: Age‐related decline in dopamine transporter binding in human striatum with [ I]β‐CIT SPECT publication-title: J Nucl Med – volume: 33 start-page: 763 year: 1994 end-page: 768 article-title: Effect of l‐deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake publication-title: Neuropharmacology – volume: 56 start-page: 192 year: 1991 end-page: 198 article-title: The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus publication-title: J Neurochem – volume: 37 start-page: 222 year: 1996 end-page: 227 article-title: Reproducibility of [ I]β‐CIT SPECT brain measurement of dopamine transporters in healthy human subjects publication-title: J Nucl Med – volume: 90 start-page: 11965 year: 1993 end-page: 11969 article-title: Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease publication-title: Proc Natl Acad Sci USA – volume: 14 start-page: 982 year: 1994 end-page: 994 article-title: Graphical, kinetic, and equilibrium analyses of [ I]β‐CIT binding to dopamine transporters in healthy human subjects publication-title: J Cereb Blood Flow Metab – volume: 34 start-page: 423 year: 1993 end-page: 431 article-title: Positron emission tomographic imaging of the dopamine transporter with C‐11‐Win 35,428 reveals marked declines in mild Parkinson's disease publication-title: Ann Neurol – volume: 294 start-page: 577 year: 1995 end-page: 583 article-title: The vesicular monoamine transporter is not regulated by dopaminergic drug treatments publication-title: Eur J Pharmacol – volume: 2 start-page: 153 year: 1987 end-page: 164 |
SSID | ssj0011516 |
Score | 1.9955329 |
Snippet | The effect of subchronic treatment with l‐dopa/carbidopa or l‐selegiline on striatal dopamine transporters (DAT) was examined in patients with idiopathic... The effect of subchronic treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporters (DAT) was examined in patients with idiopathic... |
SourceID | proquest pubmed pascalfrancis wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 436 |
SubjectTerms | Aged Anticonvulsants. Antiepileptics. Antiparkinson agents Antiparkinson Agents - therapeutic use Biological and medical sciences Biological Transport Carbidopa - therapeutic use Cocaine - analogs & derivatives Corpus Striatum - diagnostic imaging Corpus Striatum - metabolism Dopamine - metabolism Dopamine transporter Drug Therapy, Combination Female Humans Iodine Radioisotopes Levodopa - therapeutic use Male Medical sciences Monoamine Oxidase - metabolism Neuropharmacology Occipital Lobe - metabolism Parkinson Disease - diagnostic imaging Parkinson Disease - drug therapy Parkinson's disease Pharmacology. Drug treatments Selegiline - pharmacology Selegiline - therapeutic use SPECT Tomography, Emission-Computed, Single-Photon Treatment Outcome |
Title | Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT |
URI | https://api.istex.fr/ark:/67375/WNG-9BGN5T9K-3/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2F1531-8257%28199905%2914%3A3%3C436%3A%3AAID-MDS1008%3E3.0.CO%3B2-J https://www.ncbi.nlm.nih.gov/pubmed/10348466 https://search.proquest.com/docview/69786645 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV3dbtMwFLamXUzcwPjvYOALiuAibRLbcVIQ0pZ1WwvtEOu0SQhZceyialoz9UdCXO0RuOBJeBAegifhnLjNNsQlQoqqyI19VJ9z4u-4x98h5Bm3JrGZtB5nceTxHD4yWNY8a6QcGuZDP9zQ7_Wj_SPePREnK2S6PAvj-CGqDTf0jPJ9jQ6e6WnzkjQUXDXwIL6RSGgEMMcXEDsHHBTL6izlLII7uLY6O15v5xA5bOqszRp-Iz2os-3Q68J7Gwn4EEh9qCinACCV5VLB-UR5sniNJAuZzUriCyfvZcBb7DVIarWuSHnjZLwCCQB4UVdfMOEym8KcD12xjL-h2evguFzddm-R78t5cUktp435TDfyr39QRv7niVsnNxdomW45875NVuz4DlnrLfIB7pILR75MiyGtMuYpbi3Td78uvpniPGvm2USP8I4Wk7IVy0t9HuHPoMWYlmVLIACh-MgZNs4quvcJPXzfTgd0dFaWcnIDf4RFuPPp5w8YKe0M7pGj3fYg3fcWNSW8EfLYeFZoniE9aWwsrMs6YwHE5UYLnZtQWhHqWPIMGqzAA2q5r7Ufm1hbQDZg7obdJ6vjYmwfEmqkkDwKjeC5ARhk8IhvwvycDcM8GrKgRp6X2lfnjjdEZZNTTKOTQh3391SyvdcXg-StYjWyec08qg6BlACwkxp5ujQXBc6P_-hkY1vMpypKZBxFXNTIA2dFl119xgFaRjXSL23hyhdIUx0qtAKFVqCcDUAMqJgC7StQvFooHlp8lR6oUHWXTRv_esBH5IajwsAk0sdkdTaZ200AejP9pPTM33XoOU4 |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV3dbtMwFLbGkAY3_P8UGPMFRXCRNontOCkIacu6tV3bTawTkxCykthF1bRm6loJcbVH4IYX2YPsIXgSzonbbENcIqSoitzYR_U5J_6Oe_wdQl5xoyOTSONwFgYOz-AjgWXNMVrKoWYu9MMN_V4_aB3wzqE4XCLTxVkYyw9RbrihZxTva3Rw3JCuX7KGgq96DgQ4EhmNAOe4AoJnj4NmWZXFnAVwB9d6e9Ppbe4jiU2VNVnNrcW7VbbhO50b5Ca8JkQRiH0sSacAIhUFU8H9RHG2eIVEc6H1UuQbK_CtxxvsPYhqNK6I-WCFvAMRAHlRW98w5TI5hVkf2nIZf8Oz1-Fxsb5t3SU_FzNj01qOarNpWsu-_0Ea-b-n7h65MwfMdN1a-H2yZMYPyEpvnhLwkJxZ_mWaD2mZNE9xd5l2f5390PlJUs-SSTrCO5pPilasMPV1hL-D5mNaVC6BGITiI8fYOC0Z3yd0f68ZD-jouKjmZAf-DOtw-8vFOYwUtwePyMFWcxC3nHlZCWeEVDaOESlPkKE01AaW5jRhHoTmOhVppn1phJ-GkifQYASeUcvcNHVDHaYGwA1YvGaPyfI4H5unhGopJA98LXimAQlpPOUbMTdjQz8LhsyrkNeF-tWJpQ5RyeQIM-mkUJ_62yra2O6LQbSjWIWsXrOPsoMnJWDsqELWFvaiwP_xT51kbPLZqQoiGQYBFxXyxJrRZVeXcUCXQYX0C2O48gUyVfsKrUChFShrAxAGKqZA-woUr-aKhxZXxbvKV51F07N_PeAaudUa9Lqq2-7vPCe3LTMG5pS-IMvTycysAu6bpi8LN_0NL8I9cA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV3dbtMwFLbGkCpu-P8pMOYLiuAibRI7cVIQ0pa2W7u1m7ZOTELISmIHVdOaqj8S4mqPwAVPwoPwEDwJ58RttiEuEVIVRW7so_qcU3_HOf4OIS-5VqGOhbY4C3yLp3CJYVmztBIiU8yGfrih3x_4uye8d-qdrpHZ6iyM4YcoN9zQM4r_a3Twicoal6Sh4KqOBfGNQEIjgDm2B7Gzw0GxrMYizny4g89Wt2X1W8fIYVNjbVa369FBjW27Vu8Gucl95qIrtI5KzilASEW9VPA-rzhaXCHhUmijFPnaCHzj8CZ7B6KazSti3hshb0EEIF5U1hfMuIxnMOmZqZbxNzh7HR0Xy1vnDvm-mhiT1XJWX8yTevr1D87I_zxzd8ntJVymW8a-75E1Pb5PKv1lQsADcmHYl2me0TJlnuLeMt3_dfFN5ZO4kcbTZIR3NJ8WrVhf6vMIfwbNx7SoWwIRCMVHzrFxXvK9T-nxYTsa0tF5UcvJDPwRVuHup58_YKSoO3xITjrtYbRrLYtKWCMksrG0l_AY-UkDpWFhTmLmQGCuEi9JlSu05yaB4DE0aA9PqKV2ktiBChIN0AbsXbFHZH2cj_UTQpXwBPdd5fFUAQ5SeMY3ZHbKMjf1M-ZUyatC-3JiiENkPD3DPDrhyQ-DHRlu7wy8YbgnWZVsXDOPsoMjBCDssEo2V-YiwfvxlU481vliJv1QBL7PvSp5bKzosqvNOGBLv0oGhS1c-QJ5ql2JViDRCqSxAQgCJZOgfQmKl0vFQ4stowPpyt6q6em_HnCTVA5bHbnfHew9I7cMLQYmlD4n6_PpQm8A6JsnLwon_Q0l1zwf |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+treatment+with+L-dopa%2Fcarbidopa+or+L-selegiline+on+striatal+dopamine+transporter+SPECT+imaging+with+%5B123I%5Dbeta-CIT&rft.jtitle=Movement+disorders&rft.au=Innis%2C+R+B&rft.au=Marek%2C+K+L&rft.au=Sheff%2C+K&rft.au=Zoghbi%2C+S&rft.date=1999-05-01&rft.issn=0885-3185&rft.volume=14&rft.issue=3&rft.spage=436&rft_id=info:doi/10.1002%2F1531-8257%28199905%2914%3A3%3C436%3A%3AAID-MDS1008%3E3.0.CO%3B2-J&rft_id=info%3Apmid%2F10348466&rft.externalDocID=10348466 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0885-3185&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0885-3185&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0885-3185&client=summon |